BAH243

Lentiviral vector BAH243 · Essen Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BAH243, covering 2024-11-05 to 2024-11-05. Get the full timeline:

Most recent: Clinical Trial Update: Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease [Phase 1, Phase 2]

See pricing